Skip to content

A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci

A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01040143
Acronym
Pneucast
Enrollment
450
Registered
2009-12-29
Start date
2008-01-31
Completion date
2010-03-31
Last updated
2019-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumococcal Disease

Keywords

Pneumococci, Streptococcus pneumoniae

Brief summary

A study taking swabs from the back of the nose (nasopharynx) to look at carriage of pneumococci.

Interventions

None listed

Sponsors

Public Health England
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Born in a cohort eligible for routine or catch up pneumococcal conjugate vaccination (i.e. date of birth since 4th September 2004) or a family member where a child is eligible and has been enrolled * Written informed consent given by the subject's parent/ legal guardian as well as assent from the child after the nature of the study has been explained to them or * Written informed consent given by the subject after the nature of the study has been explained to them

Exclusion criteria

* Moderate to severe disability. * Cerebral palsy, syndromes and neurological disorders affecting swallowing. * Ear Nose and Throat disorders affecting the anatomy of the ear,i.e.malformed ears. * Confirmed or suspected immunodeficiency (congenital or acquired). * On immunosuppressive therapy.

Design outcomes

Primary

MeasureTime frame
Presence of pneumococci in nasopharyngeal swabs

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026